MedTrace Logo

A Study Comparing The Safety, Tolerability and Efficacy of Trizivir VS Combivir & Atazanavir In Subjects With HIV

NCT00082394 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2017-05-24

No results posted yet for this study

Summary

The aim of this study was to assess whether TRIZIVIR, administered twice-daily was as safe, tolerable and efficacious as a combination of the drugs COMBIVIR administered twice-daily and atazanavir administered once daily. Over the course of 48 weeks, various parameters that measure safety, tolerability and efficacy of the investigational drugs were measured and compared.

Conditions

  • Infection, Human Immunodeficiency Virus I
  • HIV Infection

Interventions

DRUG

Trizivir

DRUG

atazanavir

DRUG

Combivir

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-04-26
Primary Completion
2006-03-01
Completion
2006-03-01

Countries

  • United States
  • Mexico

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00082394 on ClinicalTrials.gov